Skip to main content

Table 2 The incidence of grade1-2 TRAEs and grade ≥ 3 TRAEs

From: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis

TRAE Name

Studies

Grade1-2

Grade ≥ 3

Heterogeneity rate (95% CI) %

Heterogeneity rate (95% CI) %

Diarrhoea

15–21,23,24,26–28,30

Random 28 (18, 38)

Random 4 (2, 6)

Rash

15–20,21,23,24,27,28,30

Random 15 (9, 21)

Random 2 (1, 3)

Fatigue

15–20,21,23,24,26–28,30

Random 26 (17, 35)

Random 4 (2, 6)

Nausea

15–20,23,24,26–28

Random 21 (14, 28)

Random 1 (0, 2)

Poor appetite

18–20,23,24,26–28,30

Random 23 (14, 33)

Random 2 (0, 4)

Abdominal pain

15,17,20,24,26,28,30

Random 15 (8, 23)

Random 3 (1, 5)

Pyrexia

15–17,20,23,24,26,27,30

Random 16 (11, 21)

Random 2 (0, 3)

Increased AST

16,17,20,23,27,28

Random 16 (5, 27)

Random 4 (2, 6)

Increased ALT

15–17,20,27,28

Random 12 (5, 19)

Random 3 (2, 5)

Hypothyroidism

15–17,20,23,27,30

Random 11 (7, 16)

Random 1 (− 1, 2)

Pancreatitis

13,14,16,17,24,25

Random 7 (2, 12)

Random 5 (1, 9)